Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Increase in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 121,900 shares, a growth of 12.6% from the September 30th total of 108,300 shares. Based on an average daily trading volume, of 279,800 shares, the short-interest ratio is presently 0.4 days. Approximately 0.4% of the company’s shares are short sold.

Coeptis Therapeutics Price Performance

Shares of NASDAQ:COEP traded down $0.01 during trading hours on Thursday, hitting $0.20. 158,724 shares of the company’s stock traded hands, compared to its average volume of 319,749. Coeptis Therapeutics has a 1 year low of $0.15 and a 1 year high of $1.33. The business has a fifty day moving average price of $0.19 and a 200-day moving average price of $0.26. The firm has a market capitalization of $7.94 million, a P/E ratio of -0.44 and a beta of -0.91.

Coeptis Therapeutics (NASDAQ:COEP) last announced its earnings results on Friday, August 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, equities analysts predict that Coeptis Therapeutics will post -0.26 earnings per share for the current year.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.